Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena, Anna Gallí, Esperanza Such, et al.
Blood (2016) Vol. 128, Iss. 10, pp. 1408-1417
Open Access | Times Cited: 300

Showing 1-25 of 300 citing articles:

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1200-1228
Open Access | Times Cited: 1676
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms
Laura Palomo, Manja Meggendorfer, Stephan Hütter, et al.
Blood (2020) Vol. 136, Iss. 16, pp. 1851-1862
Open Access | Times Cited: 151
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 143
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2022) Vol. 97, Iss. 3, pp. 352-372
Closed Access | Times Cited: 72
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 6, pp. 1142-1165
Open Access | Times Cited: 24
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2019) Vol. 95, Iss. 1, pp. 97-115
Open Access | Times Cited: 119
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent, Attilio Orazi, Michael R. Savona, et al.
Haematologica (2019) Vol. 104, Iss. 10, pp. 1935-1949
Open Access | Times Cited: 118
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management
Mrinal M. Patnaik, Ayalew Tefferi
American Journal of Hematology (2018) Vol. 93, Iss. 6, pp. 824-840
Open Access | Times Cited: 111
How I treat chronic myelomonocytic leukemia
Éric Solary, Raphaël Itzykson
Blood (2017) Vol. 130, Iss. 2, pp. 126-136
Open Access | Times Cited: 106
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Raphaël Itzykson, Pierre Fenaux, David Bowen, et al.
HemaSphere (2018) Vol. 2, Iss. 6
Open Access | Times Cited: 103
Genomic determinants of chronic myelomonocytic leukemia
Bhumika J. Patel, B Przychodzen, Swapna Thota, et al.
Leukemia (2017) Vol. 31, Iss. 12, pp. 2815-2823
Open Access | Times Cited: 96
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients
Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, et al.
Leukemia (2019) Vol. 34, Iss. 5, pp. 1407-1421
Closed Access | Times Cited: 84
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Wenbin Xiao, Alexander Chan, Michael R. Waarts, et al.
Blood (2020) Vol. 137, Iss. 10, pp. 1377-1391
Open Access | Times Cited: 82
MDS overlap disorders and diagnostic boundaries
Tiffany Tanaka, Rafael Bejar
Blood (2019) Vol. 133, Iss. 10, pp. 1086-1095
Open Access | Times Cited: 80
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr, Denis Vorobyev, Terra L. Lasho, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 67
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 10, pp. e756-e765
Closed Access | Times Cited: 60
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Àlex Bataller, Guillermo Montalban‐Bravo, Alexandre Bazinet, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e186-e195
Closed Access | Times Cited: 10
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity
Hiroyoshi Kunimoto, Cem Meydan, Abbas Nazir, et al.
Cancer Cell (2017) Vol. 33, Iss. 1, pp. 44-59.e8
Open Access | Times Cited: 84
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
Matthieu Duchmann, Fevzi Yalniz, Alessandro Sanna, et al.
EBioMedicine (2018) Vol. 31, pp. 174-181
Open Access | Times Cited: 78
Turning the tide in myelodysplastic/myeloproliferative neoplasms
Michael W. Deininger, Jeffrey W. Tyner, Éric Solary
Nature reviews. Cancer (2017) Vol. 17, Iss. 7, pp. 425-440
Closed Access | Times Cited: 76
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
Mrinal M. Patnaik, Daniela Barraco, Terra L. Lasho, et al.
American Journal of Hematology (2016) Vol. 92, Iss. 1, pp. 56-61
Open Access | Times Cited: 66
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
Valeria Santini, B Allione, Gina Zini, et al.
Leukemia (2017) Vol. 32, Iss. 2, pp. 413-418
Open Access | Times Cited: 65
The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis
Catherine Cargo, Matthew Cullen, Jan Taylor, et al.
Blood (2019) Vol. 133, Iss. 12, pp. 1325-1334
Open Access | Times Cited: 64
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
Julia T. Geyer, Wayne Tam, Yen-Chun Liu, et al.
Modern Pathology (2017) Vol. 30, Iss. 9, pp. 1213-1222
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top